Citation
- Authors: Miyasato, Y., Yoshizawa, T., Sato, Y., Nakagawa, T., Miyasato, Y., Kakizoe, Y., Kuwabara, T., Adachi, M., Ianni, A., Braun, T., Komohara, Y., Mukoyama, M., Yamagata, K.
- Year: 2018
- Journal: Sci Rep 8 5927
- Applications: in vitro / DNA / jetPRIME
- Cell types:
- Name: HEK-293T
Description: Human embryonic kidney Fibroblast
Known as: HEK293T, 293T - Name: NRK-52E
- Name: HEK-293T
Abstract
Cisplatin-induced acute kidney injury (AKI) has been recognized as one of cisplatin's serious side effects, limiting its use in cancer therapy. Sirtuin 1 (SIRT1) and SIRT3 play protective roles against cisplatin-induced kidney injury. However, the role of SIRT7 in cisplatin-induced kidney injury is not yet known. In this study, we found that Sirt7 knockout (KO) mice were resistant to cisplatin-induced AKI. Furthermore, our studies identified that loss of SIRT7 decreases the expression of tumor necrosis factor-alpha (TNF-alpha) by regulating the nuclear expression of the transcription factor nuclear factor kappa B. It has been reported that cisplatin-induced nephrotoxicity is mediated by TNF-alpha. Our results indicate that SIRT7 plays an important role in cisplatin-induced AKI and suggest the possibility of SIRT7 as a novel therapeutic target for cisplatin-induced nephrotoxicity.
